Nov 2026· Diabetes Research and Clinical Practice· pp.
113646
· 0 citations· 46 references
Medicine
TL;DR
Subcutaneous semaglutide produces meaningful SBP reduction across diverse patient populations, with minimal DBP changes.
Abstract
Hypertension remains a leading contributor to cardiovascular disease globally. Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), reduces blood pressure in clinical trials, but the consistency and magnitude of this effect across populations is unclear. We conducted a systematic review and meta-analysis of placebo-controlled randomized trials reporting blood pressure changes in patients receiving subcutaneous semaglutide. MEDLINE, Web of Science, and Embase were searched through December 2025. Pooled weighted mean differences with 95% confidence intervals were calculated using random-effects inverse-variance models. Cochrane's RoB 2.0 assessed risk of bias, and the Grading of recommendations Assessment Development and Evaluation (GRADE) approach was used to evaluate the certainty of the evidence. Our meta-analysis included seven trials with approximately 20,000 patients. Semaglutide reduced systolic blood pressure (SBP) significantly compared with placebo across 11 arms (20,011 participants): weighted mean difference -3.46 mmHg (95% CI: -4.44 to -2.49; I2 = 29.5%; high certainty of evidence). A modest reduction in diastolic blood pressure (DBP) was also observed (-0.56 mmHg, 95% CI: -0.82 to -0.29; I2 = 0.0%; moderate certainty of evidence). However, sensitivity analysis revealed that the DBP effect was dependent on a single large study, with loss of significance upon its exclusion. Subcutaneous semaglutide produces meaningful SBP reduction across diverse patient populations, with minimal DBP changes. Blood pressure improvement represents one component of semaglutide's cardiometabolic benefits.
Background: Optimal blood pressure (BP) control remains elusive for millions of patients worldwide, often leading to resistant or secondary hypertension. Overactivation of the mineralocorticoid receptor (MR) drives this systemic pathology. While steroidal mineralocorticoid receptor antagonists (MRAs) are effective, the...
G. Marino, S. D. Di Fusco, E. Graziano et al.· Journal of Clinical Medicine· 0 citations
Overall, zilebesiran produced significant and consistent BP reductions, especially in ambulatory measures, with a favorable safety profile, and builds on previous meta-analyses that included only 2 RCTs; this updated analysis reflects the need for novel therapeutic options.
Muhammad Hussain, Muhammad Hassan, Asharib Sohaib et al.· European Journal of Clinical...· 2 citations
BACKGROUND
Cardiovascular death (CVD) remains a leading cause of global mortality. Although semaglutide reduces major adverse cardiovascular events (MACE), the consistency and exact magnitude of its standalone effect on CVD across various patient phenotypes require comprehensive evaluation. This meta-analysis systemati...
G. Marino, S. Aquilani, S. D. Di Fusco et al.· Critical Pathways in Cardiol...· 0 citations
Peripheral arterial occlusive disease (PAOD) outcomes are rarely prespecified in randomised type 2 diabetes trials, limiting comparative inference across glucagon-like peptide-1 receptor agonists (GLP-1RAs).
To compare GLP-1RA regimens for PAOD risk in adults with type 2 diabetes.
We conducted a PRI...
R. Amani-Beni, B. Darouei, S. Maleki et al.· European Heart Journal· 0 citations
Nebivolol functions as a third-generation, highly selective beta1-adrenoceptor antagonist distinguished by its nitric oxide-inducing vasodilatory capabilities.
The current network meta-analysis (NMA) was designed to appraise the clinical effectiveness and safety profile of nebivolol in contrast to placebo...
R. Kreutz, B. Rayner, E. Mustapha et al.· European Heart Journal· 0 citations